CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
Published on February 9, 2024
Graphite Bio, Inc.
611 Gateway Blvd, Suite 120
South San Francisco, CA 94080
February 9, 2024
VIA EDGAR
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street NE
Washington, DC 20549
Attention: | Ms. Doris Stacey Gama |
Mr. Jason Drory |
Mr. Eric Atallah |
Ms. Lynn Dicker |
Re: | Graphite Bio, Inc. |
Acceleration Request for Registration Statement on Form S-4
File No. 333-275919
Requested Date: | February 13, 2024 |
Requested Time: | 4:15 p.m. Eastern Time |
Dear. Ms. Gama, Mr. Drory, Mr. Atallah and Ms. Dicker:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the Act), Graphite Bio, Inc. (the Company) hereby requests that the effective date of the above-referenced registration statement (the Registration Statement) be accelerated to February 13, 2024, at 4:15 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Andrew Goodman at (617) 570-1861. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Andrew Goodman, by email to agoodman@goodwinlaw.com or by facsimile to (212) 937-3172.
If you have any questions regarding this request, please contact Andrew Goodman of Goodwin Procter LLP at (617) 570-1861.
Sincerely, | ||
Graphite Bio, Inc. | ||
By: | /s/ Kimberlee C. Drapkin | |
Kimberlee C. Drapkin | ||
Interim President and Chief Executive Officer |
cc: | Andrew Goodman, Goodwin Procter LLP |
Maggie L. Wong, Goodwin Procter LLP
Shoaib Ghias, Goodwin Procter LLP
Tevia K. Pollard, Goodwin Procter LLP